(Reuters) - Shares of Cara Therapeutics surged more than 20 percent on Wednesday after it signed a licensing agreement with Vifor Fresenius Medical Care Renal Pharma Ltd that could give the U.S. drug developer up to $470 million in milestone payments.
Cara Therapeutics signs licensing deal with Vifor Fresenius, shares surge
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться